Results 1 to 10 of about 137,417 (261)

Drugs for treating myocardial fibrosis

Frontiers in Pharmacology, 2023
Myocardial fibrosis, which is a common pathological manifestation of many cardiovascular diseases, is characterized by excessive proliferation, collagen deposition and abnormal distribution of extracellular matrix fibroblasts.
Zhanhong Ren, Zixuan Zhang, Zixuan Zhang, Li Ling, Xiufen Liu, Xin Wang   +5 more
doaj   +3 more sources

RNA 5-Methylcytosine Modification in Myocardial Fibrosis [PDF]

Reviews in Cardiovascular Medicine
Myocardial fibrosis represents a common pathological hallmark of various cardiovascular diseases progressing to heart failure, with the immunoinflammatory response playing a pivotal role in the pathogenesis of myocardial fibrosis.
Bohan Li, Yan Hao, Wendan Tian, Wei Liu
doaj   +2 more sources

Roles of Biomarkers in Myocardial Fibrosis [PDF]

Aging and disease, 2020
Myocardial fibrosis is observed in various cardiovascular diseases and plays a key role in the impairment of cardiac function. Endomyocardial biopsy, as the gold standard for the diagnosis of myocardial fibrosis, has limitations in terms of clinical application.
Shichao Lv, Junping Zhang, Yanyang Li
exaly   +3 more sources

Assessment of Nonischemic Myocardial Fibrosis

Journal of the American College of Cardiology, 2010
Myocardial fibrosis is recognized as the pathologic entity of extracellular matrix remodeling. Diffuse, reactive fibrosis is being increasingly recognized in a variety of conditions despite the absence of ischemia. Regardless of the etiology, fibrosis leads to increased myocardial stiffness thereby promoting cardiac dysfunction.
, , Christine Jellis
exaly   +6 more sources

Palmitoylated SARM1 targeting P4HA1 promotes collagen deposition and myocardial fibrosis: A new target for anti-myocardial fibrosis [PDF]

Acta Pharmaceutica Sinica B
Myocardial fibrosis is a serious cause of heart failure and even sudden cardiac death. However, the mechanisms underlying myocardial ischemia-induced cardiac fibrosis remain unclear.
Xuewen Yang, Yanwei Zhang, Xiaoping Leng, Yanying Wang, Manyu Gong, Dongping Liu, Haodong Li, Zhiyuan Du, Zhuo Wang, Lina Xuan, Ting Zhang, Han Sun, Xiyang Zhang, Jie Liu, Tong Liu, Tiantian Gong, Zhengyang Li, Shengqi Liang, Lihua Sun, Lei Jiao, Baofeng Yang, Ying Zhang   +21 more
doaj   +2 more sources

Myocardial fibrosis in primary aldosteronism. [PDF]

Front Endocrinol (Lausanne)
ObjectiveWe investigated myocardial fibrosis in relation to clinical and biochemical characteristics and the metabolomics in patients with primary aldosteronism.MethodsOur study included 54 patients with primary aldosteronism. We performed cardiac magnetic resonance to evaluate focal replacement myocardial fibrosis defined as late gadolinium ...
Chen YL, Chen CH, Ye XF, Xu JZ, Zhu LM, Xu TY, Li Y, Wang JG.   +7 more
europepmc   +4 more sources

Immunomodulation of Myocardial Fibrosis

JACC: Basic to Translational Science, 2023
Immunotherapy is a potential cornerstone in the treatment of myocardial fibrosis. During a myocardial insult or heart failure, danger signals stimulate innate immune cells to produce chemokines and profibrotic cytokines, which initiate self-escalating inflammatory processes by attracting and stimulating adaptive immune cells. Stimulation of fibroblasts
Sikking, Maurits A., Stroeks, Sophie L.VM., Marelli-Berg, Federica, Heymans, Stephane R.B., Ludewig, Burkhard, Verdonschot, Job A.J.   +5 more
openaire   +4 more sources

Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction

Journal of Cardiovascular Development and Disease, 2023
(1) Background: Chronic inflammation and fibrosis are key players in cardiac remodeling associated with left ventricular hypertrophy (LVH) and heart failure with a preserved ejection fraction (HFpEF). Monocytes and T-helpers (Th) are involved in both pro-
Artem Ovchinnikov, Anastasiya Filatova, Alexandra Potekhina, Tatiana Arefieva, Anna Gvozdeva, Fail Ageev, Evgeny Belyavskiy   +6 more
doaj   +1 more source

Myocardial fibrosis [PDF]

Tidsskrift for Den norske legeforening, 2018
Myokardfibrose oppstår sekundært til kardial belastning eller skade. I denne oversiktsartikkelen presenteres sentrale aspekter ved myokardfibrose.Vi foretok 2 søk i PubMed som til sammen ga 417 treff. Artiklenes relevans ble vurdert på grunnlag av tittel, sammendrag og eventuell fulltekst. 44 sentrale artikler ble inkludert.Myokardfibrose klassifiseres
Torvald, Espeland, Ida Gjervold, Lunde, Brage, H Amundsen, Lars, Gullestad, Svend, Aakhus   +4 more
openaire   +2 more sources

Myocardial Fibrosis in Athletes [PDF]

Mayo Clinic Proceedings, 2016
Myocardial fibrosis (MF) is a common phenomenon in the late stages of diverse cardiac diseases and is a predictive factor for sudden cardiac death. Myocardial fibrosis detected by magnetic resonance imaging has also been reported in athletes. Regular exercise improves cardiovascular health, but there may be a limit of benefit in the exercise dose ...
van de Schoor, Freek R., Aengevaeren, Vincent L., Hopman, Maria T.E., Oxborough, David L., George, Keith P., Thompson, Paul D., Eijsvogels, Thijs M.H.   +6 more
openaire   +3 more sources